Europe Epilepsy Drugs Market Forecast to 2030 - Regional Analysis

List of Tables

The Europe epilepsy drugs market was valued at US$ 1,941.16 million in 2022 and is expected to reach US$ 2,626.05 million by 2030; it is estimated to grow at a CAGR of 3.8% from 2022 to 2030.

Increasing Number of Elderly People Fuels the Europe Epilepsy Drugs Market

Epilepsy is one of the prevalent neurological disorders affecting the geriatric population. According to the National Center for Biotechnology Information, epilepsy is the third most common neurological disorder affecting the elderly after dementia and stroke. The incidence of epilepsy is increasing in older adults, partly because of the growing prevalence of stroke, brain tumors, and dementia. Considering that modern society is aging, the overall prevalence and incidence of epilepsy are expected to rise.

The Eurostat statistics indicate that over one-fifth (21.1%) of the European population was aged 65 or more in 2022. According to an article published by UpToDate Inc. in August 2021, the incidence rate of epilepsy rises with age and is highest among patients aged 75 and above.

Therefore, due to the growing geriatric population, there is notable surge in conditions such as epilepsy owing to which the market for epilepsy drugs witnesses a significant growth.

Europe Epilepsy Drugs Market Overview

The Europe epilepsy drugs market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. The region holds a significant market share in the epilepsy drugs market. The European epilepsy drugs market is expected to witness significant growth during the forecast period due to factors such as the significant growth in elderly population, approvals of new drugs by regulatory authorities, increase in funding by governments to improve and develop effective drugs and treatments for seizures in the region.

Europe Epilepsy Drugs Market Revenue and Forecast to 2030 (US$ Million)

Europe Epilepsy Drugs Market Segmentation

The Europe epilepsy drugs market is segmented into treatment, distribution channel, and country.

Based on treatment, the Europe epilepsy drugs market is classified into first generation anti-epileptics, second generation anti-epileptics, and third generation anti-epileptics. The third-generation anti-epileptics segment held the largest share in 2022.

In terms of distribution channel, the Europe epilepsy drugs market is categorized into hospital pharmacy, retail pharmacy stores, and others. The hospital pharmacy segment held the largest share in 2022.

Based on country, the Europe epilepsy drugs market is segmented Germany, the UK, France, Italy, Spain, and the Rest of Europe. The UK dominated the Europe epilepsy drugs market in 2022.

Abbott Laboratories, Alkem Laboratories Ltd, GSK Plc, Novartis AG, Pfizer Inc, Sanofi SA, Teva Pharmaceutical Industries Ltd, and UCB SA are some of the leading companies operating in the Europe epilepsy drugs market.

Product Code: BMIRE00029809

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Epilepsy Drugs Landscape

4.1 Overview

5. Europe Epilepsy Drugs Market - Key Industry Dynamics

5.1 Market Drivers
- 5.1.1 Growing Prevalence of Epilepsy
- 5.1.2 Increasing Number of Elderly People
5.2 Market Restraints
- 5.2.1 Recall of Therapeutic Products
5.3 Market Opportunities
- 5.3.1 Several Epilepsy Drugs Nearing Patent Expiration
5.4 Future Trends
- 5.4.1 Increasing Product Approvals
5.5 Impact Analysis

6. Epilepsy Drugs Market - Europe Market Analysis

6.1 Overview
6.2 Europe Epilepsy Drugs Market Revenue (US$ Mn), 2022 - 2030

7. Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Treatment

7.1 Overview
7.2 Europe Epilepsy Drugs Market Revenue Share, by Treatment 2022 & 2030 (%)
7.3 First Generation Antiepileptics
- 7.3.1 Overview
- 7.3.2 First Generation Antiepileptics: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Second Generation Anti-epileptics
- 7.4.1 Overview
- 7.4.2 Second Generation Anti-epileptics: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Third Generation Anti-epileptics
- 7.5.1 Overview
- 7.5.2 Third Generation Anti-epileptics: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 - by Distribution Channel

8.1 Overview
8.2 Europe Epilepsy Drugs Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
8.3 Hospital Pharmacy
- 8.3.1 Overview
- 8.3.2 Hospital Pharmacy: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Retail Pharmacy Stores
- 8.4.1 Overview
- 8.4.2 Retail Pharmacy Stores: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
- 8.5.1 Overview
- 8.5.2 Others: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 - Country Analysis

9.1 Europe Epilepsy Drugs Market, by Key Country - Revenue (2022) (US$ Million)
- 9.1.1 Europe Epilepsy Drugs Market, by Country, 2022 & 2030 (%)
  - 9.1.1.1 Germany: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 Overview
    - 9.1.1.1.2 Germany: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.3 Germany: Europe Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.1.1.4 Germany: Europe Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.2 France: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 Overview
    - 9.1.1.2.2 France: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.3 France: Europe Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.1.2.4 France: Europe Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.3 UK: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 Overview
    - 9.1.1.3.2 UK: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.3 UK: Europe Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.1.3.4 UK: Europe Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.4 Italy: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.1 Overview
    - 9.1.1.4.2 Italy: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.3 Italy: Europe Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.1.4.4 Italy: Europe Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.5 Spain: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.1 Overview
    - 9.1.1.5.2 Spain: Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.3 Spain: Europe Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.1.5.4 Spain: Europe Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)
  - 9.1.1.6 Rest of Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.6.1 Overview
    - 9.1.1.6.2 Rest of Europe Epilepsy Drugs Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.6.3 Rest of Europe Epilepsy Drugs Market, by Treatment, 2020-2030 (US$ Million)
    - 9.1.1.6.4 Rest of Europe Epilepsy Drugs Market, by Distribution Channel, 2020-2030 (US$ Million)

10. Epilepsy Drugs Market-Industry Landscape

10.1 Overview
10.2 Growth Strategies in the Epilepsy Drugs Market
10.3 Inorganic Growth Strategies
- 10.3.1 Overview
10.4 Organic Growth Strategies
- 10.4.1 Overview

11. Company Profiles

11.1 UCB SA
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Novartis AG
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 Pfizer Inc
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 GSK Plc
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Abbott Laboratories
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Sanofi SA
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Teva Pharmaceutical Industries Ltd
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Alkem Laboratories Ltd
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments

12. Appendix

12.1 About Us
12.2 Glossary of Terms